Dexcom INC 8-K filings

DexCom announced robust second quarter 2026 financial results, exceeding expectations with a 13% revenue increase and raising its full-year guidance.

DexCom shareholders successfully elected twelve directors, ratified its auditor, and approved executive compensation at the 2026 Annual Meeting.

Dexcom, Inc. announced Kevin R. Sayer's return from temporary leave to resume his role as Executive Chairman with a new compensation package.

Dexcom strengthens its board with the appointment of Google executive Rick Osterloh, bringing extensive tech and product leadership.

Dexcom reported strong fourth quarter and full year 2025 financial results, driven by significant revenue growth and strategic product launches, while reiterating robust 2026 guidance.

Dexcom reported preliminary unaudited Q4 and full-year 2025 revenue exceeding guidance, alongside a positive initial financial outlook for 2026 and a new CEO.

Dexcom, Inc. formalizes Jacob S. Leach's promotion to President and Chief Executive Officer, effective January 1, 2026, outlining his compensation package.

Dexcom reported strong third-quarter 2025 financial results with 22% revenue growth and raised its full-year 2025 guidance for revenue and other key metrics.

Dexcom, a global leader in glucose biosensing, announced the appointment of Dr. Euan Ashley, a renowned researcher and entrepreneur, to its Board of Directors.

DexCom's CEO and Chairman, Kevin R. Sayer, is taking a temporary medical leave of absence, leading to the appointment of interim leadership.

Dexcom, a leader in continuous glucose monitoring, announced robust second-quarter 2025 financial results, raised its full-year revenue guidance, and detailed a CEO succession plan with Kevin Sayer transitioning to Executive Chairman and Jacob Leach becoming CEO in 2026.

Dexcom announces the promotion of Jake Leach to President and Chief Operating Officer, effective immediately, recognizing his contributions to the company's innovation and strategic direction.

DexCom, Inc. announces the appointment of Ms. Rene Gal to the Audit Committee and the Compensation Committee of its Board of Directors, effective immediately on May 9, 2025.

DexCom stockholders approved amendments to the 2015 Equity Incentive Plan and Employee Stock Purchase Plan, increasing the number of shares available for issuance.

Karen Dahut, a director of DexCom, Inc., resigned from the Board of Directors effective May 8, 2025.

Dexcom's Q1 2025 revenue grew 12% year-over-year to $1.036 billion, with the company also announcing a $750 million share repurchase program.

DexCom dismisses Ernst & Young LLP and engages Deloitte & Touche LLP as its new independent registered public accounting firm effective March 21, 2025.

Dexcom, Inc. has appointed Rene Gal, a seasoned executive with extensive experience in the life sciences sector, to its Board of Directors, effective March 6, 2025.

DexCom received a warning letter from the FDA citing manufacturing and quality management system deficiencies, but the company anticipates no material impact on its 2025 revenue guidance.

Dexcom's revenue grew 8% year-over-year in Q4 2024 to $1.114 billion, with full-year revenue reaching $4.033 billion, an 11% increase.

Dexcom reported preliminary unaudited results for Q4 2024 and fiscal year 2024, with revenue growth and provided an initial outlook for 2025, projecting continued growth.

DexCom and Abbott have entered into a settlement and patent cross-license agreement, resolving all outstanding patent litigation between the two companies.

Dexcom's third quarter results show revenue growth of 2% year-over-year, but a decrease in operating income, alongside the launch of a new over-the-counter glucose biosensor and a leadership transition.

Dexcom reported a 15% year-over-year revenue increase for Q2 2024, launched new product features, and announced a $750 million share repurchase program.

DexCom's 2024 Annual Meeting saw the election of ten directors, ratification of the accounting firm, and votes on executive compensation and shareholder proposals.

Dexcom's first quarter 2024 results show a 24% year-over-year revenue increase, driven by strong customer growth and new product launches.

DexCom has entered into an agreement with Bank of America to terminate outstanding warrants, settling the obligation by delivering shares of common stock.

Dexcom's fourth quarter revenue grew by 27% year-over-year to $1.03 billion, driven by strong customer growth and increased adoption of its continuous glucose monitoring (CGM) technology.